Indianapolis-based pharmaceutical giant Eli Lilly announced Monday that it has agreed to acquire Calytrix Bio for up to $1.5 billion in cash to expand development of treatments for rare blood cancers.
Under the terms of the agreement, Lilly will acquire Calytrix, and Calytrix shareholders could receive up to $1.5 billion in cash, inclusive of an upfront payment and subsequent payments upon the achievement of certain clinical and regulatory milestones.
Brad Prosek, President and Chief Executive Officer of Calytrix Bio, stated: “Calytrix was founded on the belief that patients with MPNs deserve therapies that do more than manage symptoms. From the beginning, our goal has been to alter the disease course in mCALR-driven ET and MF. This transaction represents an important step toward accelerating that vision. We look forward to Lilly advancing the program through the clinic and exploring its potential to benefit patients across the disease spectrum. I am deeply grateful to our team, scientific advisors, and committed investors, each of whom has supported delivery of Calytrix’s program to the starting line for clinical development.”
J.P. Morgan Life Sciences Private Capital, the life sciences venture capital arm of J.P. Morgan Asset Management, founded Calytrix in 2025.
The move is the latest in a string of acquisitions by Lilly as it works to diversify beyond its blockbuster diabetes and weight-loss franchise, the company’s primary growth engine.
Eli Lilly And Co shares rose over 1% Monday following the announcement.
By CEO NA Editorial Staff











